The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.
L. Nogova
Other Remuneration - Bayer; Novartis
C. Mattonet
No relevant relationships to disclose
M. Scheffler
No relevant relationships to disclose
I. Papachristou
No relevant relationships to disclose
N. Muthen
No relevant relationships to disclose
M. Sos
No relevant relationships to disclose
U. T. Hacker
No relevant relationships to disclose
T. Elter
No relevant relationships to disclose
H. Backes
No relevant relationships to disclose
C. Kobe
No relevant relationships to disclose
K. Rhiem
No relevant relationships to disclose
P. Mallmann
No relevant relationships to disclose
U. Fuhr
No relevant relationships to disclose
R. Schnell
No relevant relationships to disclose
I. Katay
No relevant relationships to disclose
K. Toepelt
No relevant relationships to disclose
M. Reiser
No relevant relationships to disclose
N. Harbeck
No relevant relationships to disclose
M. Dietlein
No relevant relationships to disclose
J. Wolf
Consultant or Advisory Role - Bayer; Novartis
Research Funding - Bayer; Novartis